Published in Mov Disord on November 01, 2002
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) (2007) 0.91
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol (2008) 0.75
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak in New York City, April-May 2009. J Infect Dis (2010) 2.85
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
The syndrome of fixed dystonia: an evaluation of 103 patients. Brain (2004) 2.36
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Etiology and pathogenesis of Parkinson's disease. Mov Disord (2011) 1.80
Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord (2005) 1.77
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine (2008) 1.74
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Reimplantation of hybrid cochlear implant users with a full-length electrode after loss of residual hearing. Otol Neurotol (2008) 1.72
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord (2004) 1.69
Progressive delayed-onset dystonia after cerebral anoxic insult in adults. Mov Disord (2002) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Does normothermic normokalemic simultaneous antegrade/retrograde perfusion improve myocardial oxygenation and energy metabolism for hypertrophied hearts? Ann Thorac Surg (2007) 1.48
Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med (2013) 1.48
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain (2006) 1.48
Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord (2007) 1.44
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Mov Disord (2012) 1.44
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol (2006) 1.43
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain (2010) 1.43
Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med (2002) 1.43
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord (2003) 1.34
Cancer consultation preparation package: changing patients but not physicians is not enough. J Clin Oncol (2004) 1.34
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem (2002) 1.25
Rainbow: a tool for large-scale whole-genome sequencing data analysis using cloud computing. BMC Genomics (2013) 1.24
Survival in multiple system atrophy. Mov Disord (2008) 1.23
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
How common are complications of Parkinson's disease? J Neurol (2002) 1.19
Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol (2009) 1.18
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport (2002) 1.15
Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord (2004) 1.14
Automated Water Analyser Computer Supported System (AWACSS) Part II: Intelligent, remote-controlled, cost-effective, on-line, water-monitoring measurement system. Biosens Bioelectron (2005) 1.13
Pathogenesis of Parkinson's disease. Mov Disord (2012) 1.13
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
Health-related quality of life in multiple system atrophy. Mov Disord (2006) 1.11
A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol (2004) 1.11
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett (2002) 1.11
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord (2005) 1.09
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci (2005) 1.07
Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol (2004) 1.07
N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck (2008) 1.05
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord (2005) 1.05
Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem (2003) 1.05
Slowly progressive cerebellar ataxia and cervical dystonia: clinical presentation of a new form of spinocerebellar ataxia? Mov Disord (2003) 1.01
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res (2006) 0.99
5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem (2002) 0.99
Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2007) 0.99
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem (2004) 0.96
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol (2006) 0.96
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord (2005) 0.96
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther (2006) 0.96
Early antigen-specific response by naive CD8 T cells is not altered with aging. J Immunol (2002) 0.95
Impact of Parkinson's disease on patients' adolescent and adult children. Parkinsonism Relat Disord (2004) 0.95
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol (2004) 0.95
Progressive supranuclear palsy-like phenotype associated with bilateral hypoxic-ischemic striopallidal lesions. Mov Disord (2005) 0.94
Difference in MSA phenotype distribution between populations: genetics or environment? J Parkinsons Dis (2012) 0.92
New approaches to therapy. Int Rev Neurobiol (2011) 0.92
Alteration of central motor excitability in a patient with hemimasticatory spasm after treatment with botulinum toxin injections. Mov Disord (2006) 0.92
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci (2003) 0.91
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci (2005) 0.91
Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord (2003) 0.91
Irradiation enhances the efficiency of testicular germ cell transplantation in sheep. Biol Reprod (2009) 0.90
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther (2004) 0.90
Pallidal stimulation modifies after-effects of paired associative stimulation on motor cortex excitability in primary generalised dystonia. Exp Neurol (2007) 0.90
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis (2010) 0.89
Oxidative stress and Parkinson's disease. Handb Clin Neurol (2007) 0.89
Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem (2006) 0.89
Effects of temperature and viscosity on R67 dihydrofolate reductase catalysis. Biochemistry (2006) 0.88
Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol (2008) 0.88
Sweating dysfunction in Parkinson's disease. Mov Disord (2003) 0.88
Current development of acupuncture research in Parkinson's disease. Int Rev Neurobiol (2013) 0.88
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. J Neurosci Res (2005) 0.87
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. J Neurol (2004) 0.86
Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse. Hum Mol Genet (2008) 0.86
Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. J Neurochem (2004) 0.86
Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochem Biophys Res Commun (2005) 0.86
Molecular characterisation of resistance to ALS-inhibiting herbicides in Hordeum leporinum biotypes. Pest Manag Sci (2007) 0.85